Covenant Partners’s Neurocrine Biosciences NBIX Stock Holding History

Covenant Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,225	Closed	-$225K	–	186
2023 Q1	$225K	Buy	2,225 +282	+15%	+$29.3K	0.09%	165
2022 Q4	$232K	Buy	+1,943	New	+$228K	0.09%	155
2021 Q2	–	Sell	-2,055	Closed	-$200K	–	204
2021 Q1	$200K	Buy	+2,055	New	+$215K	0.08%	195
2020 Q4	–	Sell	-2,225	Closed	-$214K	–	193
2020 Q3	$214K	Buy	+2,225	New	+$257K	0.1%	179

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Covenant Partners's NBIX Position: Q2 2023 in Review

Covenant Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 2,225 shares — an estimated $225K sold.

Covenant Partners first reported a position in NBIX in Q3 2020 and held it in 4 quarters. The position peaked at $232K in Q4 2022. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

Covenant Partners reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
Covenant Partners sold 2,225 Neurocrine Biosciences shares in Q2 2023, an estimated $225K.
Covenant Partners first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 4 quarters.
Covenant Partners's Neurocrine Biosciences position peaked at $232K in Q4 2022.
456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Covenant Partners's 13F filing for Q2 2023, filed 11 Aug 2023.